• In early July 2026, Thermo Fisher Scientific’s Board authorized a quarterly cash dividend of US$0.47 per share and saw its RapidINTEL Plus DNA cartridge approved by the FBI’s National DNA Index System, while also joining Arcturus Therapeutics to support Phase 3 development and potential commercialization of the ARCT-032 mRNA cystic fibrosis therapy.
• Together, these developments highlight Thermo Fisher’s mix of shareholder returns, advanced forensic tools linked to the national CODIS database, and growing role as an integrated partner in complex mRNA drug programs.
• Next, we’ll examine how FBI approval of RapidINTEL Plus and the Arcturus mRNA collaboration influence Thermo Fisher’s broader investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Thermo Fisher Scientific Investment Narrative Recap

To own Thermo Fisher Scientific, you generally need to believe in its role as a core picks-and-shovels supplier to pharma, biotech, and advanced diagnostics, with steady demand across tools, services, and data. The latest dividend affirmation, RapidINTEL Plus FBI approval, and Arcturus mRNA collaboration reinforce that broad platform, but do not clearly change the most immediate swing factor: how quickly end-market demand normalizes versus ongoing margin pressures and China-related uncertainty.

Among the updates, I see the Arcturus Therapeutics collaboration as most relevant, because it deepens Thermo Fisher’s position as an end-to-end partner in complex mRNA and biologics programs. If ARCT-032 progresses, Thermo Fisher’s integrated manufacturing and clinical capabilities could become more visible as a potential earnings driver, which matters when investors are weighing slower academic and China tool demand against higher value pharma and biotech services.

Yet against this, investors should be aware that margin pressure from tariffs and policy shifts could still...

Thermo Fisher Scientific's narrative projects $54.1 billion revenue and $9.5 billion earnings by 2029. This requires 6.2% yearly revenue growth and a $2.7 billion earnings increase from $6.8 billion today.

Uncover how Thermo Fisher Scientific's forecasts yield a $590.77 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts take a far more cautious view, assuming only about US$53.8 billion of revenue and US$8.5 billion of earnings by 2029, so you may find it useful to compare their concerns about tariff driven margin pressure with how Thermo Fisher’s new Rapid DNA and mRNA moves might influence those assumptions over time.

Explore 5 other fair value estimates on Thermo Fisher Scientific - why the stock might be worth as much as 35% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Thermo Fisher Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Thermo Fisher Scientific's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.